The 2022 IAS-USA Guidelines Virtual Update: Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

The 2022 IAS-USA Guidelines Virtual Update: Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

Registration Details

  • Virtual Registration: $25.00 (USD)
  • Virtual Registration ends: Wednesday, January 11, 2023
  • Virtual Fellows: $15.00 (USD)
  • Virtual Fellows ends: Thursday, December 15, 2022


Roger J. Bedimo, MD, MS
University of Texas Southwestern Medical Center
Constance A. Benson, MD
University of California San Diego
Susan P. Buchbinder, MD
San Francisco Department of Public Health
Carlos del Rio, MD
Emory University
Ellen F. Eaton, MD
University of Alabama at Birmingham
Joseph J. Eron, Jr, MD
University of North Carolina at Chapel Hill
Huldrych F. Günthard, MD
University Hospital Zurich
Jennifer F. Hoy, MBBS
Monash University
Raphael J. Landovitz, MD, MSc
University of California Los Angeles
Clara Lehmann, MD
German Center For Infectious Research (DZIF)
Jean-Michel Molina, MD
University of Paris
Paul E. Sax, MD
Harvard Medical School
Davey M. Smith, MD
University of California San Diego
Sandra A. Springer, MD
Yale University
Melanie Thompson, MD
Melanie A. Thompson, MD
Thacker & Thompson, MD


Rajesh T. Gandhi, MD
Harvard Medical School
Michael S. Saag, MD
University of Alabama at Birmingham

December 15, 2022

1:00 PM - 5:00 PM ET

Last Modified: Jun 5, 2023 @ 11:14 AM

Program Description

This course will review the newly released Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society–USA Panel, published online by JAMA on December 1, 2022. This course will cover the key changes and updates through a novel series of presentations and interactive panel sessions presented by the experts who served on the guidelines panel. The 2022 guidelines include updated recommendations on initiating and changing antiretroviral therapy and prevention of HIV infection. New sections include recommendations for substance use disorder and mpox.

Assessment of Needs

Rapid advances in HIV disease management require the ongoing attention of practitioners involved in direct patient care. This course will address the implications of new information on strategies for the clinical management of HIV. Information will be presented through a mix of didactic lectures, clinically relevant cases, and expert panel discussions developed and led by an expert faculty of HIV/AIDS clinicians and researchers.

Learning Objectives

After participating in the activity, learners will be able to:

  • Describe the latest recommendations for managing HIV in particular clinical circumstances, such as comorbid conditions, coinfections, pregnancy, and issues in older patients
  • Initiate and monitor HIV prevention intervention strategies using the latest recommendations, including the use of postexposure prophylaxis (PEP) and preexposure prophylaxis (PrEP), in individuals at risk for HIV infection
  • Describe the most current data on currently available and newly available antiretroviral drugs and approaches
  • Describe the current best understanding of the impact of COVID-19 on HIV
  • Describe the current best understanding of the impact of mpox on HIV
  • Describe the current best understanding of the impact of substance use disorder on HIV

Conflicts of Interest

In the interest of maintaining the independence of its continuing education activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they or their spouses or partners have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the continuing education activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA continuing education activity.

The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.


Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:

  • Have a solid, working knowledge of HIV disease management
  • Provide comprehensive or specialty care for patients with HIV infection
This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.

Cancellation Policy

Cancellation requests must be made 8 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.

Continuing Education Credits

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Credits

These activities are eligible for ANCC credit, see final CNE activity announcement for specific details.

Pharmacy Credits

Accreditation Council for Pharmacy Education logo These activities are eligible for ACPE credit, see final CPE activity announcement for specific details.

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.


Gilead Sciences, Inc.
Merck & Co, Inc.
ViiV Healthcare


Janssen Therapeutics


Theratechnologies, Inc.

Frequently Asked Questions

View our list of FAQs about attending an activity.

Further Questions?
Please contact the registration department at or 415-544-9400.